Jajini Susan Varghese

Prof. Dr. Jajini Susan Varghese

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Cureus
Verified
Journal Article
Open access
PDF file
CHChristopher Hillyar
Christopher Hillyar
KRKathrine S. Rallis
Kathrine S. Rallis
JVJajini Susan Varghese
Jajini Susan Varghese
Cancer has traditionally been hailed a genetic disease, dictated by successive genetic aberrations which alter gene expression. Yet, recent advances in molecular sequencing technologies, enabling the characterisation of cancer patient phenotypes on a large scale, have highlighted epigenetic changes as a hallmark of cancer. Epigenetic modifications, including DNA methylation and demethylation and histone modifications, have been found to play a key role in the pathogenesis of a wide variety of cancers through the regulation of chromatin state, gene expression and other nuclear events. Targeting epigenetic aberrations offers remarkable promise as a potential anti-cancer therapy given the reversible nature of epigenetic changes. Hence, epigenetic therapy has emerged as a rapidly advancing field of cancer research. A plethora of epigenetic therapies which inhibit enzymes of post-translational histone modifications, so-called ‘writers’, ‘erasers’ and ‘readers’, have been developed, with several epigenetic inhibitor agents approved for use in routine clinical practice. Epigenetic therapeutics inhibit the methylation or demethylation and acetylation or deacetylation of DNA and histone proteins. Their targets include writers (DNA methyltransferases [DNMT], histone acetyltransferases [HAT] and histone deacetylases [HDAC]) and erasers (histone demethylases [HDM] and histone methylases [HMT]). With new epigenetic mechanisms increasingly being elucidated, a vast array of targets and therapeutics have been brought to the fore. This review discusses recent advances in cancer epigenetics with a focus on molecular targets and mechanisms of action of epigenetic cancer therapeutics.

21 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
PPPeeter Padrik
Peeter Padrik
NTNeeme Tonisson
Neeme Tonisson
THTone Hovda
Tone Hovda
KSKristine Kleivi Sahlberg
Kristine Kleivi Sahlberg
EHEivind Hovig
Eivind Hovig
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are increasingly applied in healthcare. One of the most studied and developed areas is predictive medicine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. This current guidance endeavours to articulate the scientific evidence underpinning the clinical utility of PRSs in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: This guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opinion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRSs can be divided into the following scenarios: (1) Management of cancer-free women with a family history of cancer; (2) individual personalised breast cancer prevention and screening in healthcare services; and (3) breast cancer screening programs for more personalised screening. Conclusions: The integration of PRSs into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, supporting a personalised, risk-based approach to breast cancer prevention and screening.

24 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MAMunaser Alamoodi
Munaser Alamoodi
UWUmar Wazir
Umar Wazir
KMKinan Mokbel
Kinan Mokbel
NPNeill Patani
Neill Patani
JVJajini Susan Varghese
Jajini Susan Varghese
Kefah MokbelKefah Mokbel
Kefah Mokbel
Recent advances in systemic treatment for breast cancer have been underpinned by recognising and exploiting subtype-specific vulnerabilities to achieve higher rates of pathologic complete response (pCR) after neo-adjuvant systemic therapy (NAST). This down-staging of disease has permitted safe surgical de-escalation in patients who respond well. Triple-negative (TNBC) or HER2-positive breast cancer is most likely to achieve complete radiological response (rCR) and pCR after NAST. Hence, for selected patients, particularly those who are clinically node-negative (cN0) at diagnosis, the probability of disease in the sentinel node after NAST could be low enough to justify omitting axillary surgery. The aim of this pooled analysis was to determine the rate of sentinel node positivity (ypN+) in patients with TNBC or HER2-positive breast cancer who were initially cN0, achieving rCR and/or pCR in the breast after NAST. MedLine was searched using appropriate search terms. Five studies (N = 3834) were included in the pooled analysis, yielding a pooled ypN+ rate of 2.16% (95% CI: 1.70–2.63). This is significantly lower than the acceptable false negative rate of sentinel lymph node biopsy (SLNB) and supports consideration of omission of SLNB in this subset of patients.

13 February 2023 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
BLBenjamin J. Langridge
Benjamin J. Langridge
SJS. Jasionowska
S. Jasionowska
HKH. Khan
H. Khan
LALaura Awad
Laura Awad
BTB.R.H. Turner
B.R.H. Turner
PBPeter Butler
Peter Butler

16 May 2022 in Epigenomics
Verified
Journal Article
Open access
CHChristopher Rt Hillyar
Christopher Rt Hillyar
SKShivani S Kanabar
Shivani S Kanabar
KRKathrine S Rallis
Kathrine S Rallis
JVJajini Susan Varghese
Jajini Susan Varghese
Cancer epigenetic mechanisms support the acquisition of hallmark characteristics during oncogenesis. EZH2 – an important histone methyltransferase that writes histone H3 lysine 27 trimethylation ma... Plain language summary Cancer epigenetics involves cellular processes that ensure that gene expression changes that enable cancer cells to outcompete their neighboring normal tissues are passed on ...

30 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
BOBerta Obispo
Berta Obispo
CBCaroline BAILLEUX
Caroline BAILLEUX
BCBlanca Cantos
Blanca Cantos
PZPilar Zamora
Pilar Zamora
SJSachin R Jhawar
Sachin R Jhawar
XXXiaoqing Xu
Xiaoqing Xu
Breast cancer (BC) is the most prevalent malignancy in women worldwide. Despite most cases being diagnosed in the early stages, patients typically require a multimodal treatment approach. This typically involves a combination of surgery, radiotherapy, systemic treatments (including chemotherapy or immunotherapy), targeted therapy, and endocrine therapy, depending on the disease subtype and the risk of recurrence. Moreover, patients with BC and germline mutations in the breast cancer genes 1 or 2 (BRCA1/BRCA2), (gBRCAm), who are typically young women, often require more aggressive therapeutic interventions. These mutations present unique characteristics that necessitate a distinct treatment approach, potentially influencing the side effect profiles of patients with BC. Regardless of the clear benefit observed with these treatments in terms of reduced recurrence and mortality rates, long-term, treatment-related adverse events occur that negatively affect the health-related quality of life (HRQoL) of BC survivors. Thus, long-term adverse events need to be factored into the treatment decision algorithm of patients with early BC (eBC). Physical, functional, emotional, and psychosocial adverse events can occur and represent a significant concern and a challenge for clinicians, patients, and their families. This review article provides an overview of the various long-term adverse events that patients with eBC may experience, including their associated risk factors, as well as management and prevention strategies. We also explore the evidence of the long-term impact of treatment on the HRQoL of patients with gBRCAm. By providing a comprehensive overview of current evidence and recommendations regarding patients’ HRQoL, we aim to equip clinicians with scientific and clinical knowledge and provide guidance to optimize care and improve long-term outcomes.